Denisse Castro, Liliana Vasquez and Mónica Oscanoa from the Departamento de Oncología Médica, Hospital Edgardo Rebagliati Martins, Essalud. Lima-Perú and the Unidad de Oncología Pediátrica y del Adolescente . Hospital Edgardo Rebagliati Martins, Essalud. Lima-Perú have published in Carcinos a article entitled : ¿Puede la quimioterapia metronómica mejorar la sobrevida libre de progresión y sobrevida global en pacientes pediátricos con sarcomas avanzados?: Experiencia preliminar.
In this article, they report their preliminary experience in 12 patients with osteosarcoma and rhabdomyosarcoma metastatic at diagnosis or at relapse. Patients would receive :
thalidomide (100mg/day)
celecoxib (200 mg/day).
alternating cyclophosphamide (100 mg/day for 3 weeks) and etopooside (50mg/day) + methotrexate (15 mg/m2, twice per week) for 3 weeks
without any break for a duration of 12 months
12 patients with osteosarcoma (8 cases) or rhabdomyosarcoma (4 cases) with a median age of 15.5 years old who previouly received 2 lines of treatment (median 1-4) are reported. Mean duration of the metronomic treatment was 12 months (range 6-25 months). PFS was 24 months (range 22-72 months). No patient stopped treatment because of toxicity. Grade III/IV toxicities were observed in 25% of the patients. After starting metronomic therapy, OS and PFS at 2 years were 90.9% (+/- 8.7) and 81.8% (+/- 11.6)
This results are surprisingly good in patients with osteosarcoma who do not seem to respond well to metronomic chemotherapy.
Free full text can be found as an attached file.
Reply to this article
discussion